Tag: <span>Lymphoma</span>

Home / Lymphoma
What causes finger joint pain?
Post

What causes finger joint pain?

Finger joint pain may affect a person’s everyday activities and may have several different causes. Some people may experience finger joint pain that worsens when they move or press on the finger. Others may have persistent finger joint pain that does not improve with rest or over-the-counter (OTC) treatment. This article discusses the causes, symptoms,...

Post

CAR T cell therapy: potential for considerable savings

GERMAN CANCER RESEARCH CENTER (DEUTSCHES KREBSFORSCHUNGSZENTRUM, DKFZ) Chimeric antigen receptor (CAR) T cell therapy is a new and in some cases highly effective form of immunotherapy to treat certain types of cancer of the blood and lymph system. This promising treatment comes at a cost, however: The manufacturers charge up to EUR 320,000 for the...

Early clinical trial supports tumor cell-based vaccine for mantle cell lymphoma
Post

Early clinical trial supports tumor cell-based vaccine for mantle cell lymphoma

by Rockefeller University Press A phase I/II clinical trial by researchers at Stanford University suggests that vaccines prepared from a patient’s own tumor cells may prevent the incurable blood cancer mantle cell lymphoma (MCL) from returning after treatment. The study, which will be published June 19 in the Journal of Experimental Medicine (JEM), reveals that...

Post

Researchers test new treatment protocol for lymphoma

Lymphoma is a type of blood cancer that develops from lymphocytes (a type of white blood cell). It has many subtypes. A rare subtype, called intravascular large B-cell lymphoma (or IVLBCL) is notably hard to diagnose accurately because the cancerous lymphocytes grow inside small blood vessels, instead of at lymph nodes, and there is no...

Post

Old weapon, new target: Dasatinib against angioimmunoblastic T-cell lymphoma

Researchers from the University of Tsukuba show that angioimmunoblastic T-cell lymphoma (AITL) is dependent on T-cell receptor (TCR) signaling and that dasatinib, a multi-kinase inhibitor that targets the TCR pathway, may improve treatment outcomes UNIVERSITY OF TSUKUBA Tsukuba, Japan – Angioimmunoblastic T-cell Lymphoma (AITL) is an intractable form of non-Hodgkin lymphoma with a bleak prognosis....

Post

Lymphoma patients may have new path to remission, even when CAR T therapy fails

Penn study shows promise of an off-the-shelf immunotherapy in relapse/refractory non-Hodgkin lymphoma UNIVERSITY OF PENNSYLVANIA SCHOOL OF MEDICINE ORLANDO – A new, experimental immunotherapy can put patients with B-cell non-Hodgkin lymphoma (NHL) that is resistant to or has come back after multiple other therapies, including CAR T therapy, into remission. A global, multi-center trial found...

Post

Leukemia, lymphoma squarely in sights of new class of drugs

UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO UT Health San Antonio researchers, working with collaborators at the University of Florida, have discovered a safe and potent next generation of drugs to fight multiple types of leukemia and lymphoma in adults and children. The journal Nature Medicine reported the findings Dec. 2. “This is...

Post

Accurate lymphoma prognosis from a simple blood test

by Kristin Samuelson, Northwestern University After a patient is diagnosed with lymphoma—an often-treatable type of cancer that attacks the lymph nodes, spleen, thymus, bone marrow and more—the natural next steps are determining the patient’s survival outlook and deciding the best course of treatment. But current methods of doing so remain inaccurate or invasive, often involving...

Post

J-shaped association seen for BMI, Hodgkin lymphoma

(HealthDay)—There is a strong positive association between body mass index (BMI) and incident Hodgkin lymphoma(HL), with the positive association seen at BMIs greater than 24.2 kg/m², according to a study recently published in the British Journal of Cancer. Helen Strongman, from the London School of Hygiene and Tropical Medicine, and colleagues examined the shape of the correlation between BMI and HL in individuals aged 16...

Post

New epigenetic drug against Mantle Cell Lymphoma

New epigenetic drug against Mantle Cell Lymphoma A new study by doctor Manel Esteller, Director of the Epigenetics and Cancer Biology Program (PEBC) of the Bellvitge Biomedical ResearchInstitute (IDIBELL), ICREA Researcher and Professor of Genetics at the University of Barcelona, presents an epigenetic drug capable of slowing down cell growth in Mantle Cell Lymphoma (MCL), a...